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Abstract
Percutaneous transluminal angioplasty (PTA) is an established method for treat‐
ment of peripheral artery disease (PAD) of the femoropopliteal artery. However, in
up to 50% of patients restenosis and/or reocclusion remain a frequent complication
occurring in the first year after the procedure. In this study, we focused on the influ‐
ence of compromised postprocedural infrapopliteal runoff of the affected limb, on
the hypercoagulability as detected by a global hemostasis assay and on genetic pre‐
disposition to hypercoagulability and on the regulation of the inflammation
through the nuclear receptor related 1 protein (NuRR1). Consecutive PAD patients
treated by femoropopliteal PTA because of disabling claudication or critical limb is‐
chemia were followed up by vascular ultrasound imaging at 1, 6, and 12 months af‐
ter the procedure. Venous blood samples for hemostasis, inflammation, and gene
analysis were obtained before and 24 h after PTA. One month after femoropopliteal
PTA, 23% of patients with compromised runoff developed the combined end point
restenosis/reocclusion in comparison to 11% with good runoff (p = 0.03). After 6
months, the differences were no longer significant. It was concluded that compro‐
mised postprocedural infrapopliteal runoff predisposes to early restenosis/reocclu‐
sion after femoropopliteal PTA and that the deterioration of infrapopliteal runoff in
the year after femoropopliteal PTA is accompanied by worsening of long-term fem‐
oropopliteal patency. Patients were genotyped for the prothrombotic gene polymor‐
phisms: platelet receptor glycoprotein IIIa T1565C, coagulation factor V G1691A,
coagulation factor II G20210A, coagulation factor XII C(-4)T, and plasminogen acti‐
vator inhibitor-1 4G5G. We were not able to show any association between these
polymorphisms and the restenosis/reocclusion rate in patients treated with femoro‐
popliteal PTA. Furthermore, no association between thrombin generation and reste‐
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nosis/reocclusion rate was established. NuRR1 haplotypes significantly increased
the restenosis/reocclusion rate after PTA (adjusted relative risks were 1.6, 95% CI
1.1–2.3 for haplotype 2 and 2.0, 95% CI 1.3–2.8 for haplotype 3). To conclude, this
study suggested a significantly higher restenosis/reocclusion rate in patients with
compromised runoff compared to patients with a good runoff 1 month after the
procedure. Hypercoagulability was not associated with the restenosis/reocclusion
rate, and the prothrombotic polymorphisms were equally distributed among pa‐
tient with and without restenosis/reocclusion, suggesting minor or no role in reste‐
nosis/reocclusion. Haplotypes 2 and 3 in the NuRR1 gene significantly increased the
restenosis/reocclusion rate, suggesting significant role of inflammation. In this on‐
going study, further analysis on a larger group of patients is warranted.
Keywords: Percutaneous transluminal angioplasty, peripheral artery disease, in‐
flammation, hemostasis
1. Introduction
Peripheral artery disease (PAD) is a prevalent circulatory problem in which narrowed or
occluded arteries reduce blood flow to the limbs. PAD is most often a manifestation of
generalized atherosclerosis that reduces the patients’ quality of life by reducing their walking
ability and also confers an increased risk for cardiac death, acute coronary syndrome, and
ischemic stroke. Patients with PAD die more than 3 times more often than peers of the same
age [1]. Early diagnosis is important for improving the patient’s quality of life and for reducing
the risk of serious secondary vascular events. PAD, defined by decreased ankle brachial
pressure index, is found in 15–20% of population aged 55 years or more [2]. All patients with
PAD require preventive treatment against vascular events by lifestyle modification and
protective medication, but only a fraction ever requires a revascularization procedure [3, 4].
This procedure is needed in order to establish suitable blood flow to the affected limb if PAD
severely hampers walking ability or in cases of critical limb ischemia [3, 4]. Percutaneous
transluminal angioplasty (PTA) is an established revascularization method for treatment of
PAD and is associated with low morbidity and mortality rates [3, 4]. However, in up to 60%
of patients, restenosis and/or reocclusion remain a frequent complication occurring in the first
year after the procedure [5]. Our understanding of the mechanisms of restenosis/reocclusion
of the femoral artery after PTA is incomplete. The comprehension of the factors that contribute
to the pathophysiology of restenosis/reocclusion is the foundation to develop effective
strategies for improvement of patients’ post-PTA outcome. Once identified, reliable predictors
of the restenosis/reocclusion risk could facilitate the use of preventive measures, help to save
healthcare resources, and assist in new drug development. In this study, we focused (i) on the
influence of compromised postprocedural infrapopliteal runoff of the affected limb, (ii) on the
hypercoagulability as detected by a global hemostasis assay and on genetic predisposition to
hypercoagulability due to altered hemostatic factors that could support thrombus formation
in the arterial segment injured by PTA, and (iii) on the regulation of the inflammation through
the nuclear receptor related 1 protein (NuRR1) that could presumable favor increased
restenosis/reocclusion rate after successful PTA.
2. Problem statement
PAD causes inadequate blood flow to the limbs, mostly lower limbs. Femoropopliteal artery
is the most commonly affected arterial segment. The patency of femoropopliteal artery after
PTA is affected by several factors [37], including clinical severity of PAD, patient comorbidities,
such as diabetes or renal failure, morphological characteristics of the arterial lesions, i.e.,
occlusion vs. stenosis, length of the lesion and their number, calcification of plaques, functional
characteristics of the affected artery, i.e., the extent of vascular inflammation, and hemody‐
namic conditions that are to a large extent defined by the arterial runoff.
The STAR registry and several older studies listed poor tibial runoff as strongly predictive of
bad long-term patency [6–10], but some authors found no association of femoral artery patency
with tibial runoff 1 year after recanalization [11]. There is not much data on the role of
concomitant infrapopliteal PTA in maintaining the long-term patency of the femoropopliteal
segment after PTA. This question is difficult to address directly since it is not ethically
acceptable to deny PTA of accessible lesions in the calf arteries to any group of patients with
clinically relevant limb ischemia who are already treated by femoropopliteal PTA.
The acute response to arterial injury induced by PTA involves the adhesion of platelets and
leukocytes, which react with the damaged arterial wall in proportion to the degree of injury.
In addition, arterial injury activates hemostasis presumably, resulting in thrombus formation
on the injured vessel segment [12]. The laboratory recognition of activated hemostasis
(hypercoagulability) is a very demanding task due to the complexity of the hemostatic system.
Hypercoagulability can be detected by global tests, such as the thrombin generation assay that
provide an overview of the entire hemostatic system, including enzymes, cofactors, and
inhibitors. With this assay hypercoagulability was detected in patients with atherothrombosis
[13]. Another approach to detect hypercoagulability is to measure specific substances (pepti‐
des, enzymes, and enzyme–inhibitor complexes) that are liberated with the activation of
hemostasis, namely, specific hemostasis activation markers such as D-dimer [14]. A permanent
prothrombotic state caused by gene polymorphisms that affect coagulation factors or platelets
could supplement hypercoagulability and contribute to increased risk for restenosis/reocclu‐
sion. Such prothrombotic polymorphisms include glycoprotein IIIa T1565C polymorphism
(GPIIIa T1565C), which increases platelet adhesion and aggregation, factor V G1691A, which
causes resistance to activated protein C, factor II G20210A associated with elevated prothrom‐
bin levels, factor XII C46T associated with lower factor XII levels, and plasminogen activator
inhibitor-1 (PAI-1) 4G5G associated with lower PAI-1 levels.
In the following months after PTA, the hyperplasia of smooth muscle cells (SMCs) in vascular
wall that is regulated by proinflammatory mediators can lead to restenosis [12, 15]. The
association between inflammation and PAD is well established, and the prognostic value of
inflammation in restenosis has also been recognized [16]. Shear stress during balloon inflation
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and vascular injury stimulates the production of proinflammatory molecules and the activa‐
tion of circulating monocytes. The level of monocyte activation and adherence to the vascular
wall, mediated by selectins and adhesion molecules, was suggested to promote late lumen loss
[17]. The regulation of the inflammation through the nuclear receptor related 1 protein
(NuRR1) has recently been associated with restenosis. NuRR1 (or NR4A2) together with
NR4A1 and NR4A3 constitutes the nuclear receptor subfamily 4, group A (NR4A). This
subfamily is also referred to as the nerve growth factor-induced protein-B subfamily of nuclear
receptors because these receptors were first described as early response transcription factors
expressed following stimulation by growth factors. All three subfamily members bind the
same response element(s). They are referred to as orphan receptors because the ligands that
may regulate their transcriptional activity have not yet been identified. These transcriptional
factors have been described in the regulation of differentiation, proliferation, apoptosis, and
survival of many different cell types [18]. Besides direct binding to the promoter of target genes,
NuRR1 modulates gene transcription by the transrepression of other transcription factors. Its
role in inflammatory responses has been recognized when the overexpression of NuRR1 in
human atherosclerotic lesions compared to normal healthy human arteries has been observed
[19]. An antiproliferative and anti-inflammatory function of NuRR1 in human SMCs and its
protective role against arterial wall injury-induced SMC-rich lesion formation in mice has been
shown [20]. The NuRR1 gene lies in one linkage disequilibrium block spanning approximately
36 kb of DNA on chromosome 2q22–2q23. Several gene polymorphisms were described in the
NuRR1 gene; however, from the three tagging single-nucleotide polymorphisms (rs1466408,
rs13428968, and rs12803), four haplotypes had been inferred with frequencies >1% that
explained 96% of the variation in this linkage disequilibrium block [21]. In patients undergoing
percutaneous coronary intervention, haplotypes 3 and 4 increased the risk of in-stent reste‐
nosis, target lesion revascularization, percutaneous coronary reinterventions, and the rate of
major cardiac events (MACE) about 2- to 3-fold in the first year after the procedure [20]. A
similar role in femoropopliteal restenosis after PTA was expected. To our knowledge, the role
of NuRR1 haplotypes in femoropopliteal restenosis after PTA has not been investigated yet,
although it could be expected.
3. Patients and methods
In our study on the effect of tibial runoff on femoropopliteal patency after PTA [22], consecutive
consenting patients with claudication or critical limb ischemia admitted for femoropopliteal
PTA to the Department of Vascular Diseases of the University Medical Centre Ljubljana have
been enrolled and prospectively followed up. In addition to femoropopliteal PTA, infrapopli‐
teal PTA has been performed in all cases when lesions of the calf arteries have been judged
suitable for intervention. At enrolment, risk factors for PAD and clinical stage of PAD by the
Fontaine classification have been determined for each patient [3]. The morphological changes
of femoropopliteal lesions have been evaluated according to the TASC II classification [3].
Ankle brachial pressure index has been measured routinely before and after PTA [23]. The
PTA procedures have been performed in a catheter laboratory by interventional radiologists.
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The ipsilateral anterograde approach via the common femoral artery has been used except in
cases of ostial lesions of the femoral artery, where the contralateral or transpopliteal approach
has been used, introducing 5 Fr sheaths for vascular access. All patients, already treated with
low-dose aspirin, have received local anesthesia and 3,000 IU heparin i.v. at the beginning of
the procedure. Most stenotic lesions have been crossed by a soft 0.035-inch J-wire (Terumo
Medical Corporation, USA) and in the majority of occlusions have been crossed by the direct
recanalization technique. Alternatively, the subintimal approach has been used in cases of
unsuccessful direct recanalization. Noncompliant balloons of 5 or 6 mm diameter from
different manufacturers have been used, depending on the vessel diameter in the adjacent
nondiseased parts. The balloons have been inflated for at least 1 min to 8 atm pressure. Stents
(nitinol self-expanding stents) have been implanted only in cases of flow-limiting dissections
or residual stenosis of >50% even after repeated balloon inflation. In patients with accessible
concomitant infrapopliteal lesions, the PTA of the calf arteries has also been performed. For
infrapopliteal lesions, 0.025-inch J-Terumo wire or 0.014/0.018-inch (Pointer, Denmark or
Invatec, Italy) wires have been used for intraluminal crossing, with balloon diameters from 2
to 3.5 mm (different manufacturers). All angiographies have been performed by the standard
digital subtraction technique. The technical success of PTA and the infrapopliteal runoff has
been evaluated by periprocedural angiography. Immediate technical success has been defined
as ≤ 50% residual angiographic stenosis [24]. Infrapopliteal runoff has been scored by a
modification of the Society for Vascular Surgery criteria, originally intended for quantifying
bypass runoff, where a higher score implies worse runoff [25]. This scoring system ascribes 3
points for occlusion throughout the vessel, 2.5 points for occlusion of less than half of the
arterial length, 2 points for maximal stenosis of 50–99%, 1 point for maximal stenosis of 20–
49%, and 0 points for less than 20% maximal stenosis. Each of the calf arteries has been ascribed
a weight, i.e., multiplication factor, of 1, and the distal popliteal artery has been ascribed a
weight of 3, with one point always added to the total score [26]. Thus, the cumulative score
for the distal popliteal artery (a maximum of 9 + 1) and for the tibial vessels (a maximum of 3
× 3) gives a maximum score of 19 [23]. We have divided the patients’ limbs into two categories:
good runoff (<5 points) and compromised runoff (≥ 5 points). In the good runoff group, a limb
has to have a patent popliteal artery and at least two patent calf arteries with less than 50%
maximal stenosis. An occlusion of one calf artery (3 points) and more than 50% stenosis in
another calf artery (2.5 points) already implies compromised runoff. Bad runoff with a score
of 11 or more points after femoropopliteal PTA implies complete occlusion of all 3 calf arteries
plus at least 20–49% residual stenosis of the popliteal artery. Some typical examples of
infrapopliteal runoff scoring are shown in Figure 1.
All subjects have examined by vascular ultrasonography (US) at 1 month (range 29–60 days),
6 months (range 6–8 months), and 12 months (range 12–16 months) after PTA to evaluate the
development of restenosis/reocclusion of the femoropoliteal arterial segment on a Vivid 3
ultrasound machine (GE Medical Systems, USA) with a linear vascular probe (Vascular 10L).
An adverse outcome of PTA has defined as identification of femoropopliteal stenosis of ≥50%,
confirmed by at least doubling of the maximal systolic velocity in comparison to a proximal
nondiseased arterial segment, or by identifying a reocclusion confirmed by the absence of a
Doppler flow signal [25]. The patency of calf arteries has been assessed by US at the third
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follow-up examination 12 months after femoropopliteal PTA and compared to the periproce‐
dural angiographic result. During US of the calf arteries, attempts have been made at visual‐
izing as much as possible of the whole length of the two tibial arteries and the peroneal artery,
i.e., interosseal artery. As in the femoropopliteal arterial segment, a stenosis of ≥50% has been
diagnosed by at least doubling of the maximal systolic velocity in comparison to a proximal
nondiseased arterial segment, whereas an occlusion has been documented in the absence of
Doppler flow signal. In addition, the Doppler waveform at the level of the ankle in each of the
three calf arteries has been compared to the waveform in the tibioperoneal trunk. A change
from triphasic to monophasic signal with a marked reduction in peak systolic velocity and a
decrease in the slope of systolic upstroke or absence of distal flow have been taken as additional
evidence of hemodynamically significant compromise of the investigated calf artery [25].
Figure 1. Examples of infrapopliteal scoring according to a modification of the Society for Vascular Surgery criteria
[25]. In each set of angiograms, the left image represents the popliteal artery and the upper calf, while the right image
represents the lower calf. (A) Good runoff with a score of 1: 3 × 0 + 1 point for a patent popliteal artery with <20%
popliteal stenosis (arrowhead) plus 3 × 0 points for patent calf arteries. (B) Good runoff with a score of 4: 3 × 0 + 1 for
the good patency of popliteal artery and 3 points for anterior tibial artery occlusion (arrowhead). (C) Compromised
runoff with a score 5.5: 3 × 0 + 1 for good popliteal patency and 2 points for >50% posterior tibial artery stenosis (lower
arrowhead) plus 2.5 points for anterior tibial artery occlusion spanning less than half of the arterial length (upper ar‐
rowhead). (D) Bad runoff with a score of 12: 3 × 1 + 1 points for 20–49% popliteal stenosis (small arrow) plus 2.5 points
for occlusion of less than half of the length of the anterior tibial artery (lower horizontal arrowhead), plus 2.5 points for
occlusion of less than half of the length of the peroneal artery with collateral filling (upper skewed arrowhead) plus 3
points for total occlusion of the posterior tibial artery with a collateral artery running along its path (lower skewed
arrowhead). Reproduced with permission from [22].
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Patients’ blood has been collected 1 day before PTA (preprocedural sample) and on the day of
PTA after the procedure (postprocedural sample). Blood has been drawn into 4.5 mL Vacu‐
tainer® tubes (Becton Dickinson, Plymouth, UK) containing 0.11 mol/L sodium citrate. From
whole blood, DNA has been extracted either manually utilizing the silica-membrane-based
DNA purification (QIAamp DNA Blood Mini Kit, Qiagen, Germany) or with magnetic beads
on an automated nucleic acid purification instrument with the iPrep™ PureLink® gDNA Blood
Kit (Life Technologies, USA). The remaining blood has been centrifuged at 2,000g and 4°C for
30 min to obtain platelet-poor plasma. Plasma has been transferred to small plastic vials, frozen
in liquid nitrogen, and stored at –70°C until analyzed.
Genotyping of prothrombotic polymorphisms (GPIIIa T1565C, factor V G1691A, factor II
G20210A, factor XII C46T and PAI-1 4G5G) and NuRR1 has been performed with real-time
PCR on an ABI PRISM 7000 system (Applied Biosystems), using TaqMan® chemistry. In
plasma, thrombin generation and D-dimer levels have been measured. Thrombin generation
has been determined using a commercial kit (Technothrombin® TGA, Technoclone, Austria),
which is based on monitoring the fluorescence generated by thrombin cleavage of a fluorogenic
substrate over time on the activation of the coagulation cascade with 5 pmol/L tissue factor.
The following parameters have been registered: lag phase, time to peak thrombin concentra‐
tion, peak thrombin concentration and area under the curve–endogenous thrombin potential
(ETP). The amount of microparticle-induced thrombin generation has also been determined
by measuring thrombin generation in microparticle-free (filtered using 0.2 μm vacuum
filtration device Ceveron® MFU-500, Technoclone, Austria) plasma versus thrombin genera‐
tion in nonfiltered plasma containing microparticles. The amount of thrombin (peak thrombin
concentration) induced by microparticles has been calculated (in per cent). D-dimer concen‐
tration has been measured with TriniLIA Auto-Dimer reagent (Trinity Biotech, Ireland) on an
automated coagulation analyzer CS2100i (Siemens Healthcare Diagnostics, Germany) [27].
4. Results and discussion
4.1. Infrapopliteal runoff
Data on the infrapopliteal runoff have been analyzed for 176 patients [22]. We found a
significantly higher restenosis/reocclusion rate in patients with compromised runoff (23%)
compared to patients with a good runoff (11%) 1 month after femoropopliteal PTA (p = 0.03,
Figure 2) [22]. The statistical significance was lost later on (after 6 months 49% in the compro‐
mised runoff group vs. 43% in the good runoff group, p = 0.49 and 57% vs. 52% after 12 months,
respectively, p = 0.51). However, in patients’ limbs with good periprocedural runoff that
deteriorated into compromised runoff in the year after PTA, femoropopliteal restenosis/
reocclusion occurred more often than in limbs which retained good runoff: 10/14 (71%) vs.
18/51 (35%), p = 0.02 [22]. The results were similar if only patients with Fontaine stages III and
IV, i.e., critical limb ischemia were regarded. These results suggest that mechanisms of
intermediate and long-term restenosis/reocclusion act simultaneously in the calf and the
femoropopliteal arterial segment. The higher rate of early femoropopliteal restenosis/reocclu‐
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sion after PTA in limbs with compromised infrapopliteal runoff could at least in part be the
consequence of a diminished arterial blood flow predisposing to thrombosis. We recorded four
early femoropopliteal reocclusions among limbs with compromised infrapopliteal runoff and
one early reocclusion among patients’ limbs with good runoff, but due to small number, the
difference was not statistically significant. Our results at 6 and 12 months suggest that the
postprocedural infrapopliteal runoff is not a prognostic indicator of intermediate and late
restenosis/reocclusion, which are mainly caused by neointimal hyperplasia and advancing
atherosclerosis.
In interpreting these results, we must keep in mind that 40% of the subjects had their infra‐
popliteal runoff improved by PTA, and that our study tested the effects of postprocedural not
preprocedural runoff of diseased arterial segments [22]. In this respect, our work differs from
previous studies that found poor runoff strongly predictive of a bad long-term outcome of
femoropopliteal PTA [57] and agrees with the finding of no effect of tibial runoff on the rate
of the 1-year patency of recanalized superficial femoral artery occlusions in patients with at
least 1 patent tibial artery in the affected limb [11]. When we calculated the outcomes with
respect to preprocedural runoff, we found no association between the rate of restenosis/
reocclusion and the infrapopliteal runoff before it was improved by PTA [22]. This finding in
combination with our results according to postprocedural runoff strongly suggests that
improving the infrapopliteal runoff by PTA delays the time to femoropopliteal restenosis/
reocclusion, which may be especially beneficial in cases of critical limb ischemia. Patients’
limbs that experienced deterioration of good postprocedural infrapopliteal runoff in the first
year after PTA were affected by an approximately doubled rate of restenosis/reocclusion of
the femoropopliteal artery in comparison with limbs that retained good runoff [22]. This means
that worsening of infrapopliteal runoff was accompanied not only by early but also by
intermediate and late femoropopliteal restenosis or reocclusion, probably due to neointimal
hyperplasia and progression of atherosclerotic disease.
The combined complication rate of the PTA in our patients was 7%: 3 minor heamatomas, 2
pseudoaneurysms (managed by conservative treatment), and 1 periprocedural thrombosis.
The average ABI improved from 0.60 ± 0.41 before PTA to 0.82 ± 0.25 after PTA (p < 0.001).
Among the 176 treated patients, 3 had minor limb amputations within 1 month after PTA (2
transmetatarsal and 1 toe amputation), 4 additional patients had limb amputations within 6
months (2 above the knee and 2 below the knee), and 5 additional patients within 12 months
(2 above the knee, 2 below the knee, and 1 with an undisclosed level of amputation). Overall,
the amputation rate was 12/176 patients (7%) after 1 year. Two patients died within 6 months
after PTA and a total of 8/176 patients (5%) died within the first year [22]. Overall, our results
with a combined femoropopliteal restenosis/reocclusion rate of 55% and a reocclusion rate of
21% 1 year after PTA [22] were comparable to the published data for patients without implan‐
tation of self-expanding femoral stents [24, 28].This was expected since we used femoral stents
only for bailout indications, i.e., in 3 out of 176 treated patients’ limbs. The clinical success of
PTA among our series of patients was demonstrated by the low 1-year amputation rate despite
the advanced stages of PAD among our patients (36% in Fontaine stage III with rest pain and
40% in Fontaine stage IV with skin ulcerations). This result is at the upper level of the reported
limb salvage rate with traditional recanalization techniques [29].
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Among our patients, no significant differences in postprocedural runoff were found with
respect to the presence of diabetes or renal failure, but there were more smokers in the group
with compromised postprocedural runoff in comparison to the group with good runoff and
more patients with hypercholesterolemia [22]. While smoking might have decreased the
feasibility of infrapopliteal PTA, the greater prevalence of hypercholesterolemia among
patients with compromised postprocedural runoff could be just a chance finding, although
hypercholesterolemia has been associated with restenosis of TASC B and C femoropopliteal
lesions after PTA [30].
Figure 2. Time course of restenosis/reocclusion rates (%) in compromised runoff (full circle) and restenosis/reocclusion
in good runoff (empty circle). Reproduced with permission from [22]. *p < 0.03
4.2. Hemostasis
To detect a possible prothrombotic state in patients referred for femoropopliteal PTA, throm‐
bin generation and D-dimer concentration were measured before and after PTA in 88 patients.
Thrombin generation assay indicates the potential of plasma to generate thrombin following
the in vitro activation of coagulation with tissue factor or another trigger. The resulting
thrombin generation curve reflects all pro- and anticoagulant reactions that regulate the
formation and inhibition of thrombin [31]. D-dimer is a specific degradation product of cross-
linked fibrin and is thus a marker of both activated coagulation and fibrinolysis. D-dimer is
best known today as the biochemical gold standard for initial assessment of hypercoagulability
in suspected venous thrombosis [32].
We detected a hemostatic shift toward hypercoagulability induced by PTA by a significantly
higher postprocedurel thrombin generation expressed by increased ETP and higher D-dimer
concentration compared to preprocedural values (Table 1). However, we found association
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neither between thrombin generation nor D-dimer (either before or after PTA) and restenosis/
reocclusion rate. No association between preprocedural thrombin generation and restenosis
rate has also been observed in another study [33]. On the other hand, preprocedural hyper‐
coagulability detected as shortening of the thromboelastometry-derived coagulation time
(<444.5 s) reliably identified patients with high-degree in-stent restenosis in the superficial
femoral artery [34]. Higher levels of preprocedural fibrinogen were also documented in
patients with restenosis compared to patients with patent arteries [35].
Before PTA After PTA p
Thrombin generation
Lag phase (min) 10.8 ± 2.5 10.8 ± 2.2 NS
Peak thrombin (nM) 385 ± 96 393 ± 80 NS
Time to peak (min) 13.6 ± 3.1 13.8 ± 2.6 NS
Velocity 157 ± 83 154 ± 81 NS
ETP 3559 ± 542 3739 ± 490 <0.001
Microparticles (%) 26.8 ± 11.1 26.0 ± 10.2 NS
D-dimer (μg/L) 168 (99–479) 242 (138–584) <0.001
ETP—endogenous thrombin potential, NS—not significant.
Table 1. Thrombin generation and D-dimer before and after PTA (mean ± standard deviation with Student’s paired t-
test p or median, 1st–3rd quartile with Wilcoxon signed-rank test p).
Genotyping of the prothrombotic polymorphisms was performed in 128 patients. All the tested
polymorphisms were equally distributed among patients with or without restenosis/reocclu‐
sion in the first year after PTA (Table 2), suggesting that these polymorphisms have probably
no major role in restenosis/reocclusion [36]. However, in order to detect possible weak
association between these polymorphisms and femoropopliteal restenosis/reocclusion rate
after PTA, a larger study population would be required.
With the exception of the study showing association of factor V G1691A with failed vascular
reconstructions in patients with PTA [37], associations between prothrombotic gene polymor‐
phisms and the risk of restenosis have been studied predominantly after percutaneous
transluminal coronary angioplasty (PTCA). GPIIIa T1565C polymorphism was associated with
higher risk of stent thrombosis after revascularization [38, 39] and with restenosis after PTCA
in some [40], but not other studies [41]. Among other prothrombotic polymorphisms, factor V
G1691A and PAI-1 4G5G may also play a role in the process of restenosis after PTCA. The
PAI-1 4G variant was associated with an increased risk of restenosis after this procedure in
contrast to factor V G1691A, which decreased the risk [42]. As far as we know, there has been
no studies on the association of GPIIIa T1565C, factor II G20210A, factor XII C46T, and PAI-1
4G5G polymorphism with restenosis/reocclusion after PTA.
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4.3. Inflammation
Genotyping of the three tagging single-nucleotide polymorphisms (rs1466408, rs13428968, and
rs12803) in the NuRR1 gene was performed in 142 patients with femoropopliteal PTA who
finished a 12-month follow-up. From these three polymorphisms, four haplotypes were
Polymorphism Restenosis/reocclusion (N = 74) Patent arteries (N = 54) p
GP IIIa T1565C
Genotype
TT
TC
CC
45 (61)
27 (36)
2 (3)
35 (65)
17 (31)
2 (4)
NS
1565C allele frequency 0.20 0.21
FVL G1691A
Genotype
GG
AG
AA
71 (96)
3 (4)
0 (0)
51 (94)
3 (6)
0 (0)
NS
1691A allele frequency 0.02 0.03 NS
Factor II G20210A
Genotype
GG
AG
AA
70 (95)
4 (5)
0 (0)
53 (98)
1 (2)
0 (0)
NS
20210A allele frequency 0.01 0.03 NS
PAI-1 4G5G
Genotype
5G5G
4G5G
4G4G
21 (28)
22 (30)
31 (42)
6 (11)
29 (54)
19 (35)
NS
4G allele frequency 0.62 0.57
FXII C46T
Genotype
CC
CT
TT
46 (62)
23 (31)
5 (7)
33 (61)
18 (33)
3 (6)
NS
FXII 46T allele frequency 0.77 0.72 NS
NS—not significant.
Table 2. Genotype in allele distribution in patients with restenosis/reocclusion or patients with patent arteries in the
first year after PTA.
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inferred as described earlier, and their frequencies were similar to that earlier observed in
Caucasian population [20]. Haplotype 1 was the most frequent and served as the reference
haplotype. Haplotypes 2 and 3 significantly increased the restenosis/reocclusion rate as shown
by the relative risks adjusted for sex, age, and Fontaine classification calculated by Cox
regression (Table 3) [43].
Haplotype rs1466408 rs13428968 rs12803 Frequency (%) Relative risk (95% CI)
Haplotype 1 T T G 49.4 -
Haplotype 2 T T T 23.3 1.6 (1.1–2.3)
Haplotype 3 T C T 19.7 2.0 (1.3–2.8)
Haplotype 4 A T T 6.6 NS
CI—confidence interval, NS—not significant.
Table 3. Composition and frequencies of the 4 NuRR1 haplotypes with frequencies >1% and adjusted relative risk
associated with each haplotype in our study population.
Similar to our study, haplotype 3 increased the risk of in-stent restenosis, target lesion
revascularization, percutaneous coronary interventions, and the rate of MACE about 2-fold in
the first year after the procedure [20]. This study reported no association of haplotype 2, while
haplotype 4 increased the risk of in-stent restenosis, target lesion revascularization, percuta‐
neous coronary interventions, and the rate of MACE about 2- to 3-fold in the first year after
the procedure [20]. We were not able to confirm an increased risk of restenosis/reocclusion in
patients with haplotype 4 probably due to the small number of patients with this haplotype,
and further analysis on a larger group of patients is warranted.
Despite a well-recognized role of inflammation in restenosis and known polymorphisms in
inflammation marker genes that influence their level or function, the influence of these
polymorphisms on restenosis rate has not yet been extensively studied. In addition, most
studies to date focused on patients with PTCA rather than PTA. Among the most extensively
studied polymorphisms is the angiotensin-converting enzyme (ACE) insertion/deletion (I/D)
polymorphism in intron 16 of the ACE gene. Meta-analysis of 33 cohort studies involving
11,099 subjects confirmed that carriers of the ACE DD genotype are subjected to a significantly
increased risk (odds ratio 1.61, 95% CI 1.27–2.04, p < 0.001) for post-PTCA restenosis [44].
In patients with femoropopliteal PTA, two studies were reported that involved gene poly‐
morphisms in interleukins. In the first study, a combined effect of the interleukin-1B C(-511)T
single-nucleotide polymorphism and a variable number tandem repeat polymorphism in
intron 2 of the interleukin-1 receptor antagonist gene (IL-1RN VNTR) were associated with a
higher restenosis risk [45]. In the second study, a 2.4-fold increased adjusted risk for restenosis
was observed in carriers of the interleukin-6 (-174)CC genotype compared to carriers of the
(-174)GG genotype [46].
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5. Conclusion
Our understanding of the mechanisms of restenosis/reocclusion of the femoral artery after
PTA is deficient, and this study provided some additional evidence on the subject. The study
suggested a significantly higher restenosis/reocclusion rate in patients with compromised
runoff compared to patients with a good runoff 1 month after the procedure. In all patients,
hypercoagulability as assessed by a thrombin generation assay and D-dimer was observed
after PTA but was not associated with the restenosis/reocclusion rate. Prothrombotic poly‐
morphisms were equally distributed among patient with and without restenosis/reocclusion
suggesting minor or no role of these polymorphisms in the risk of restenosis/reocclusion. On
the other hand, haplotypes 2 and 3 in the NuRR1 gene significantly increased the restenosis/
reocclusion rate, suggesting significant role of inflammation. In this ongoing study, further
analysis on a larger group of patients is warranted, and possible consideration of combinations
of genetic markers rather than isolated polymorphisms in the analysis of this multifactorial
vascular disease might provide further evidence on the risk of restenosis/reocclusion after
PTA.
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